Atossa Therapeutics announces first patient dosing of Z-endoxifen

Atossa Therapeutics announced that the first patient has been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator, (Z)-endoxifen, in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ study. “Ductal Carcinoma In Situ is pre-invasive cancer, but the current standard of care is to treat it like early-stage invasive breast cancer, which for most patients involves surgery, followed by radiation treatment for three to four weeks and finally hormone therapy for five years,” Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “This is an overly aggressive treatment approach, especially when you consider most DCIS cases will not progress to invasive breast cancer if left untreated. We feel treatment with (Z)-endoxifen has the potential to replace the current standard of care, which would spare a significant percentage of patients diagnosed with DCIS from undergoing aggressive, invasive, unnecessary treatment.”